GSK PLC ADR (GSK) News

GSK PLC ADR (GSK): $35.35

0.32 (+0.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter GSK News Items

GSK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GSK News Highlights

  • For GSK, its 30 day story count is now at 22.
  • Over the past 24 days, the trend for GSK's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • SNY, DRUG and TOP are the most mentioned tickers in articles about GSK.

Latest GSK News From Around the Web

Below are the latest news stories about GSK PLC that investors may wish to consider to help them evaluate GSK as an investment opportunity.

How big a threat is Zantac really?

A story of cancer scares, secretive short sellers, psychological tape bombs and post-investment stress disorder

Yahoo | November 29, 2022

25 Countries with Highest Life Expectancy

In this article, we will be taking a look at the 25 countries with highest life expectancy. To skip our detailed analysis, you can go directly to see 10 Countries with Highest Life Expectancy. In just the past two decades, 2000 — 2019, the average global life expectancy increased from 66.8 years to 73.4 years […]

Yahoo | November 26, 2022

10 Best Biotech Stocks To Buy According To Hedge Funds

In this article, we discuss 10 best biotech stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy According To Hedge Funds. In 2023, digitalization will increase in the biotech industry as the possibility of online and remote assessment, diagnosis, […]

Yahoo | November 25, 2022

15 Biggest European Pharmaceutical Companies

In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […]

Yahoo | November 23, 2022

PRESS DIGEST-British Business - Nov 23

The following are the top stories on the business pages of British newspapers. A potential blockbuster blood cancer treatment Blenrep being developed by GSK Plc is to be removed from the American market after a request from regulators. Cristiano Ronaldo has left Manchester United Plc without receiving any compensation after the two parties agreed to rip up his contract.

Yahoo | November 23, 2022

After Disappointing Confirmatory Study, GSK To Withdraw Approved Blood Cancer Drug In US

GSK plc (NYSE: GSK) has initiated the withdrawal process of the U.S. marketing authorization for Blenrep (belantamab mafodotin-blmf) following the FDA request. This request was based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial, which did not meet the requirements of the FDA Accelerated Approval regulations. Blenrep is a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies. Also see

Yahoo | November 22, 2022

GSK to withdraw Blenrep’s U.S. marketing authorization after FDA request

The pharmaceutical giant said the request comes after its Dreamm-3 Phase 3 study didn't meet its primary endpoint of progression-free survival.

Yahoo | November 22, 2022

UPDATE 4-GSK to stop selling blood cancer drug Blenrep in United States

GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday, in another setback for the British drugmaker's oncology business. The company had said this month that Blenrep had failed the main goal of a key study designed to show it was better than an existing treatment on the market, stoking fears that regulatory approval could be rescinded by the U.S. Food and Drug Administration (FDA). On Tuesday GSK said it has begun the process to withdraw Blenrep's marketing authorisation in the country but would continue trial programmes for the drug, adding that some patients would have the option to enrol for continued access to the treatment.

Yahoo | November 22, 2022

Billionaire Steve Cohen’s Top 10 Dividend Stocks

In this article, we will take a look at billionaire Steve Cohen’s top dividend stocks. If you want to see more of billionaire Steve Cohen’s top dividend stocks, go directly to Billionaire Steve Cohen’s Top 5 Dividend Stocks. Billionaire Steve Cohen is the founder of Point72 Asset Management which as of the end of September […]

Yahoo | November 19, 2022

Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?

Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.

Yahoo | November 18, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5447 seconds.